Previous 10 | Next 10 |
Oral levodopa is the gold standard treatment for motor symptoms in individuals diagnosed with Parkinson’s disease, despite the risk of dyskinesia (sudden uncontrolled movements) related to long-term use of levodopa Published preclinical data in widely used MPTP non-human primate mo...
Vistagen Therapeutics (NASDAQ: VTGN) , a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, is releasing its 2023 fiscal year report. Highlights...
2023-06-28 16:32:00 ET VistaGen Therapeutics press release ( NASDAQ: VTGN ): FY GAAP EPS of -$8.51 misses by $0.11 . At March 31, 2023, the Company had cash and cash equivalents of approximately $16.6 million. As of June 27, 2023, the Company had 7,872,479 shares o...
Positive results in Phase 3 open label study of fasedienol (PH94B) in social anxiety disorder (SAD) Positive U.S. Food and Drug Administration (FDA) feedback on the use of the Liebowitz Social Anxiety Scale (LSAS) as the primary efficacy endpoint in future Phase 3 studies of fasedienol in...
Vistagen Therapeutics (NASDAQ: VTGN) , a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, will host a conference call and webcast today at 1:3...
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced it will host a conference call and webcast on Wednesday, June 28...
2023-06-23 09:42:51 ET Vistagen ( NASDAQ: VTGN ) received a letter from Nasdaq indicating that the company has regained full compliance with listing rules, the company said Friday. The company said it satisfied Nasdaq's minimum $1.00 bid price per share or greater require...
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that, on June 22, 2023, Vistagen received a letter from the List...
Vistagen (NASDAQ: VTGN) , a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has announced favorable safety and tolerability data from its U.S...
The U.S. Phase 1 data build on successful Phase 1 and Phase 2A clinical studies of itruvone previously conducted outside the U.S. Itruvone was well-tolerated and demonstrated a favorable safety and tolerability profile across single and multiple dose intranasal administrations ...
News, Short Squeeze, Breakout and More Instantly...
VistaGen Therapeutics Inc. Company Name:
VTGN Stock Symbol:
NASDAQ Market:
VistaGen Therapeutics Inc. Website:
Vistagen Therapeutics (NASDAQ: VTGN ), a clinical-stage, neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, has received multiple new patent...
Vistagen (Nasdaq: VTGN), a clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today announced the broadening of its global in...
Vistagen (NASDAQ: VTGN) , a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it has been recognized by Mental Health America (“MHA”) for its dedication to pr...